Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 12,742 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Male Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Real-Time Acute Kidney Injury Perioperative Prediction Clinical Trial

NCT07604662
View directory record Official record
Conditions
Acute Kidney Injury, Surgery Complications, Anesthesia
Interventions
EHR-Embedded AKI Risk Score, EHR-Embedded AKI Risk Score with Best Practice Advisory
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25,518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 2:30 PM EDT
Recruiting No phase listed Observational

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

NCT07225127
View directory record Official record
Conditions
Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

NCT00090103
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older · Male only
Enrollment
4,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
113
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

NCT00117286
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
17
States / cities
Homewood, Alabama • Anaheim, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

NCT03237988
View directory record Official record
Conditions
Healthy Subjects
Interventions
CPI-444 Capsules, CPI-444 Tablets
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

NCT00045227
View directory record Official record
Conditions
Prostate Cancer
Interventions
recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, recombinant vaccinia-B7.1 vaccine, sargramostim, docetaxel
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 28, 2026, 2:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

NCT04946370
View directory record Official record
Conditions
Prostate Cancer
Interventions
225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 28, 2026, 2:30 PM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

NCT06126380
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
AT-1501, Tacrolimus
Drug
Lead sponsor
Eledon Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

NCT01184820
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))
Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 28, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

NCT05361720
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cabozantinib, Ipilimumab, Nivolumab
Drug · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Duarte, California • Orange, California • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

TEST-ON - Does iStim Reduce Urinary Urgency?

NCT04957524
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome, Urinary Frequency More Than Once at Night
Interventions
iStim TENS unit and Transvaginal Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

NCT03735680
View directory record Official record
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer
Interventions
ONM-100
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Lighting Intervention for Cancer-related Fatigue

NCT04827446
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Hematologic Malignancy, Survivorship, Fatigue
Interventions
Wearable Sensor, Blue-blocking glasses, Clear glasses, Full SYNC app, "Dummy" SYNC app
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Abiraterone Post Ketoconazole for Prostate Cancer

NCT01199146
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vasopressin Effects on Human Social Communication

NCT01327027
View directory record Official record
Conditions
Healthy
Interventions
Vasopressin, Arginine, ADH, Placebo; Sterile Saline
Drug
Lead sponsor
Bowdoin College
Other
Eligibility
18 Years to 30 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 28, 2026, 2:30 PM EDT
Completed No phase listed Observational

A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors

NCT02978586
View directory record Official record
Conditions
Prostate-specific Membrane Antigen Positive Tumors, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
[Ga-68]PSMA PET/MR
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 28, 2026, 2:30 PM EDT
Recruiting No phase listed Observational

Optimizing Pulsatility During Cardiopulmonary Bypass

NCT05344573
View directory record Official record
Conditions
Endothelial Dysfunction, Acute Kidney Injury
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making

NCT01558583
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer, Prostate Cancer
Interventions
Rating and Ranking Task, Discrete Choice Task, Balance Sheet Task
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Penile Traction Therapy Using a Novel Device

NCT03389854
View directory record Official record
Conditions
Penile Diseases
Interventions
RestoreX PTT - randomized and open label, RestoreX PTT - open label phase only
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Results available

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

NCT05335005
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Failure, Chronic
Interventions
MK-2060
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 28, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional Results available

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

NCT02612194
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms
Interventions
Crizotinib
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 28, 2026, 2:30 PM EDT
Active, not recruiting No phase listed Observational

Post-Market Clinical Follow-Up onTVT EXACT® Continence System

NCT04829994
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Intervention
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
3
States / cities
Durham, North Carolina • North Wales, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration

NCT06278766
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-552
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 28, 2026, 2:30 PM EDT
Completed Not applicable Interventional

CHESS: Human and Computer Mentors for Prostate Cancer Patients

NCT00516256
View directory record Official record
Conditions
Prostate Cancer
Interventions
CHESS System, Cancer Information Mentor
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
3
States / cities
Hartford, Connecticut • Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 28, 2026, 2:30 PM EDT